SAN DIEGO, CA --(Marketwired - December 06, 2016) - Medical Marijuana, Inc. (OTC PINK: MJNA), the world's leading cannabis portfolio company and first-ever publicly traded cannabis company in the United States, announced today that its major investment company AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC PINK: AXIM) received approval from the Medical Ethical Committee (METC) of Wageningen University in The Netherlands to begin a study on patients suffering from irritable bowel syndrome (IBS) with the AXIM's product CanChew Plus® CBD-containing chewing gum.
"We congratulate AXIM on yet another step forward toward full clinical trials on cannabis-based treatments," said Dr. Stuart Titus, CEO of Medical Marijuana Inc. "With the global treatment market for irritable bowel syndrome estimated to grow in value to $1.5 billion by 2023, cannabis-based products like CanChew Plus® can provide viable solutions for patients suffering from some of the most common of functional gastrointestinal disorders."
"It is the goal of our family of companies and for AXIM to help people suffering from various gastrointestinal disorders with no effective remedies such as IBD and Crohn's disease. Positive outcomes from these type of studies can help in the immediate need to enter trials for inflammatory bowel disease (IBD) and Crohn's disease."
METC at Wageningen University is an institutional approval board that is compliant with the Ethical Principles for Medical Research adopted at the 18th World Medical Association (WMA) General Assembly in Helsinki, Finland, in June 1964.
Wageningen University is a world-class education and research institute in the field of life sciences, agricultural and environmental science, and the only university in The Netherlands to focus on the theme of "healthy food and living environment." According to the Times Higher Education World University Rankings, Wageningen is the best university in The Netherlands and No. 1 worldwide in agriculture and forestry for 2016 on the QS World University Rankings.
About Medical Marijuana, Inc.
Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally-friendly, economically sustainable businesses, while increasing shareholder value. For details on Medical Marijuana, Inc.'s portfolio and investment companies, visit www.medicalmarijuanainc.com.
To see Medical Marijuana, Inc.'s video statement, click here. Shareholders are also encouraged to visit the Medical Marijuana, Inc. Shop for discounted products.
AXIM® Biotechnologies, Inc. (OTC PINK: AXIM) focuses on the research, development and production of cannabis-based pharmaceutical, nutraceutical and cosmetic products. Our flagship products include CanChew®, a CBD-based controlled release chewing gum, and MedChew Rx, a combination CBD/THC gum that is undergoing clinical trials for the treatment of pain and spasticity associated with multiple sclerosis. We prioritize the well-being of our customers while embracing a solid fiscal strategy. Medical Marijuana, Inc. is a major investor in AXIM. For more information, visit www.AXIMBiotech.com.
About CanChew® and CanChew Plus®
CanChew® is a unique hemp-derived CBD functional chewing gum that is distinctly different than any other brands of gum on the market. Features listed on the CanChew® website include:
- Non-habit forming
- No prescription needed
- Available in all 50 states
- Great-tasting mint gum has no artificial sweeteners or preservatives
- Non-GMO, gluten free, vegan and kosher
CanChew Plus® is a vastly improved delivery system than the alpha version of CanChew® Gum. It is produced by a leading European functional gum manufacturer.
Featured in Healthy Living Magazine, CanChew® was also recognized by the HealthyLivinG Foundation and honored with its Triple Leaf Award.
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Axim Biotechnologies, Inc. to be materially different from the statements made herein
AXIM® Biotechnologies does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA).